Published in Hum Vaccin Immunother on July 26, 2016
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer | NCT01644968
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol (2003) 5.01
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 4.99
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 3.74
The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72
Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A (2004) 2.27
Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science (2012) 2.26
Peripheral tolerance of CD8 T lymphocytes. Immunity (2005) 2.21
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004) 2.12
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell (2015) 1.85
Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol (2013) 1.70
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer (2015) 1.66
OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57
Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33
Harnessing the power of the immune system to target cancer. Annu Rev Med (2012) 1.33
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2014) 1.30
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res (2012) 1.20
PD-1 Blockers. Cell (2015) 1.18
Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol (2015) 1.17
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One (2014) 1.13
Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol (2015) 1.11
Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res (2011) 1.05
Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res (2013) 1.03
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol (2009) 1.03
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol (2015) 1.01
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol (2007) 1.00
Immune targeting in breast cancer. Oncology (Williston Park) (2015) 0.99
Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91
Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling. J Immunol (2013) 0.89
Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. PLoS One (2012) 0.88
Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production. J Immunol (2009) 0.87
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Front Oncol (2015) 0.86
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci U S A (2016) 0.85
Clinical deployment of antibodies for treatment of melanoma. Mol Immunol (2015) 0.82
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts. Oncoimmunology (2014) 0.79
Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice. J Immunol (2010) 0.79